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Abstract. The aim of this study was to assess the treatment 
patterns and safety of sunitinib, sorafenib and bevacizumab in 
real-world clinical settings in US, Europe and Asia. Medical 
records were abstracted at 18 community oncology clinics in 
the US and at 21 tertiary oncology centers in US, Europe and 
Asia for 883 patients ≥18 years who had histologically/cyto-
logically confirmed diagnosis of advanced RCC and received 
sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) 
as first-line treatment. No prior treatment was permitted. 
Data were collected on all adverse events (AEs) and treatment 
modifications, including discontinuation, interruption and dose 
reduction. Treatment duration was estimated using Kaplan-
Meier analysis. Demographics were similar across treatment 
groups and regions. Median treatment duration ranged from 
6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for 
sunitinib, sorafenib and bevacizumab patients, respectively. 
Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of 
sunitinib, sorafenib and bevacizumab patients, respectively. 
Treatment discontinuations occurred in 62.4 (Asia) to 63.1% 
(US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 
66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treat-
ment modifications due to AEs occurred in 55.1, 54.2 and 50.0% 
sunitinib, sorafenib and bevacizumab patients, respectively. 
This study in a large, global cohort of advanced RCC patients 
found that angiogenesis inhibitors are associated with high rates 
of AEs and treatment modifications. Findings suggest an unmet 
need for more tolerable agents for RCC treatment.
Introduction
Given that nearly 25% of all patients with kidney cancer 
present with locally advanced or metastatic renal cell carci-
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noma (RCC), kidney cancer is a malignancy with a poor 
prognosis (1). Conventional therapies, such as chemotherapy 
and radiation therapy are not effective and only 10 to 20% 
of patients benefit from immunotherapy (2-4). Recently 
enhanced understanding of the etiology of advanced RCC has 
led to the development of angiogenesis inhibitor agents.
In randomized clinical trials (RCTs), first generation 
angiogenesis inhibitors sunitinib, sorafenib and bevacizumab 
plus interferon α, have demonstrated efficacy in prolonging 
progression-free survival and/or overall survival as first-line 
treatment (4-6). The efficacy of sunitinib and sorafenib has 
also been established in expanded access programs (EAP) 
(7,8). Due to their strong efficacy profiles, these agents have 
become the new standard of treatment for advanced RCC. 
All these drugs were approved by corresponding regulatory 
agencies for use in the US, Europe and Asia (9-13).
However, RCTs and EAPs have also demonstrated that 
these angiogenesis inhibitors are associated with high rates 
of toxicity and treatment modifications, including discon-
tinuations and dose changes. Since clinical trials may not be 
representative of real-life clinical practice due to treatment 
selection criteria, observational studies are necessary to 
understand the effects of treatment in the wider population 
of patients who actually receive these therapies. Small obser-
vational studies conducted in real-world clinical practice 
settings in US, Korea, Japan and Europe have provided further 
evidence of high toxicity profiles associated with these agents 
(14-21). Data from these varied care settings highlight that 
adverse events (AEs) in advanced RCC patients receiving 
angiogenesis therapies are common and often lead to treat-
ment modifications, including treatment discontinuation.
As the use of angiogenesis inhibitors rises over time and 
treatment paradigms continue to evolve, there is a critical 
need to gain a thorough understanding of toxicity profiles 
and treatment patterns of these agents across various real-
world clinical settings. Therefore, the goal of this study was 
to examine the toxicity profiles of sunitinib, sorafenib, and 
bevacizumab in advanced RCC among patients treated in 
US, Europe and Asia, and describe how clinicians in these 
settings modify treatment according to patient experiences.
Materials and methods
Study design. A retrospective study was conducted using 
data from medical records for eligible patients with advanced 
RCC who received anti-angiogenic therapies. The observa-
tion period for each patient started from the date of first 
angiogenesis inhibitor prescription or administration to the 
earliest of date of death, last follow-up date at the clinic or 
date of medical record abstraction. Data on second-line 
angiogenesis inhibitor treatment were also abstracted. The 
study drugs sunitinib, sorafenib and bevacizumab are manu-
factured by Pfizer, Bayer Healthcare Pharmaceuticals, and 
Hoffmann-LaRoche Inc., respectively.
Study population. To become eligible in the study patients 
were required to meet the following inclusion criteria: i) have 
had a confirmed histological and/or cytological diagnosis 
of locally advanced or metastatic RCC; ii) 18 years old or 
older at the time of confirmed diagnosis of advanced RCC; 
and iii) received at least 1 dose of oral sunitinib or sorafenib 
or intravenous (IV) administration of bevacizumab with or 
without interferon, after January 1, 2005. Previous immu-
notherapy or chemotherapy was not allowed. Patients were 
excluded if their first angiogenesis inhibitor treatment was 
initiated less than three months prior to the start date of 
medical record data abstraction, which varied across sites, to 
ensure adequate follow-up time.
Data source. Medical records for eligible patients were retro-
spectively abstracted by the clinical staff at 18 community 
oncology clinics in the US, and at 21 tertiary oncology centers 
across US (n=2), Europe (n=11; France n=2, Ireland n=3, Italy 
n=1, Spain n=2 and UK n=3), and Asia (n=8; Korea n=3 and 
Taiwan n=5). Data collected included date of RCC diag-
nosis, sociodemographic information, comorbidities, prior 
radiological treatments, metastatic site(s), baseline Eastern 
Cooperative Oncology Group (ECOG) performance status, 
dates and doses of anti-angiogenesis therapies prescribed 
or administered, reasons for changes in anti-angiogenesis 
therapies, and information on AEs. Other key data elements 
abstracted included the first and last dates of sunitinib, 
sorafenib and bevacizumab treatments, treatment modifica-
tions, and baseline and follow-up tumor measurements. Data 
were collected using a web-based case report form (CRF) 
created for this study. Data collection for this study spanned 
from July, 2007 through May, 2011. This study was approved 
in all centers by the ethics committees for tertiary oncology 
clinics and the New England Institutional Review Board for 
oncology community clinics in the US.
Outcome definitions
Assessment of toxicity. All toxicity was analyzed retrospec-
tively according to the experience recorded by investigators 
in daily clinical practice. AEs were graded using the National 
Cancer Institute Common Terminology Criteria for AEs 
(CTCAE) version 3.0. (22). If the severity of the AE was 
unknown then grade 1 was assigned. Only AEs experienced 
by patients during their first-line angiogenesis inhibitor treat-
ment were considered for the assessment of safety.
Assessment of treatment patterns. Treatment modifica-
tions that occurred during first-line angiogenesis inhibitor 
treatment were examined. Reasons for treatment modifica-
tions were also abstracted from patients' medical records, if 
available. Treatment modifications considered were treatment 
discontinuation, treatment interruption (temporary stoppage 
of treatment with intent to resume treatment), dose reduction 
and dose increase. Patterns of switching between different 
angiogenesis inhibitors to second-line treatment were also 
examined, including reasons for switching.
Treatment duration. The duration of first-line treatment 
extended from the date of initiation of treatment to the date 
of treatment end, death, or last follow-up, whichever occurred 
first. Patients who did not discontinue their treatment were 
censored at the last follow-up.
Statistical analysis. Descriptive statistics were used to 
characterize baseline patient characteristics and report AE 
occurrences, and treatment patterns. Means and medians 
were used to describe continuous variables while frequen-
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cies and proportions were used to describe categorical 
variables. The Kaplan-Meier survival analysis method was 
used to calculate median treatment duration and account 
for censoring. The corresponding 95% confidence intervals 
(CI) were calculated using the log transformation method. 
All analyses were performed using SAS software version 9.2 
(SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics. Table Ι presents the baseline char-
acteristics of the patients. A total of 883 patients satisfied 
the eligibility criteria, including 157 (US), 349 (Europe), 
and 125 (Asia) patients treated with sunitinib; 131 (US), 60 
(Europe), and 16 (Asia) patients treated with sorafenib; and 
22 (US), 20 (Europe), and 3 (Asia) patients treated with beva-
cizumab. Most patients across the three geographical regions 
initiated treatment on recommended dosing: 50 mg QD 4/2 
for sunitinib [range: 44.8% (Asia) to 84.8% (Europe)], 400 mg 
BID for sorafenib [range: 68.8% (Asia) to 80.0% (Europe)], 
and 10 mg/kg Q2WK for bevacizumab [range: 66.7% (Asia) 
to 91.0% (US)].
Toxicity profile. Table ΙΙ presents the rates of all grade and 
grade 3/4 AEs. The proportion of sunitinib patients experi-
encing at least one AE was about 87% across all regions. 
Among patients receiving sorafenib, 78.3% (Europe) to 
87.8% (US) experienced at least one AE, and among patients 
receiving bevacizumab, 33.3% (Asia) to 77.3% (US) experi-
enced at least one AE. Specific AEs experienced by at least 
5% of patients in at least one treatment group are reported. 
The three most common all grade AEs in patients treated 
with sunitinib were fatigue/asthenia [range: 18.4% (Asia) 
to 58.5% (Europe)], mucositis/stomatitis [range: 22.9% 
(US) to 42.1% (Europe)] and diarrhea [range: 17.6% (Asia) 
to 34.4% (US)]. Patients treated with sorafenib commonly 
experienced the following all grade AEs: fatigue/asthenia 
[range: 6.3% (Asia) to 39.7% (US)], diarrhea [range: 6.7% 
(Asia) to 35.1% (US)], and nausea [range: 5.0% (Europe) to 
23.7% (US)]. Among patients who received bevacizumab, the 
most common all grade AEs reported on the medical charts 
were fatigue/asthenia [up to 45.4% (US)] and proteinuria [up 
to 22.7% (US)].
Treatment patterns. Table III summarizes treatment patterns 
for first-line treatment with angiogenesis inhibitor. Median 
treatment duration, in months, was 6.1 (US), 10.7 (Europe) and 
10.7 (Asia) for sunitinib; 5.1 (US), 8.5 (Europe) and 7.1 (Asia) 
for sorafenib; and 9.2 (US), 9.8 (Europe) and 7.5 (Asia) 
for bevacizumab. Treatment discontinuation occurred in 
62.4% (Asia) to 63.1% (US) of patients treated with sunitinib, 
68.8% (Asia) to 90.0% (Europe) of patients treated with 
sorafenib, and 66.7% (Asia) to 81.8% (US) of patients treated 
with bevacizumab. Reasons for treatment modifications 
were available at all but one site. Among sites with these 
data, progressive disease was the most commonly recorded 
reason for treatment discontinuation [sunitinib, 33.1% (US) 
to 40.0% (Asia); sorafenib, 42.0% (US) to 55.6% (Europe); 
bevacizumab, 33.3% (Asia) to 46.7% (Europe)] followed 
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6.3% (Asia) to 28.2% (US); bevacizumab, 0% (Asia) to 
27.3% (US)]. Drug dosage was reduced in 34.4% (US) to 
48.0% (Asia) of patients treated with sunitinib, and 21.7% 
(Europe) to 45.8% (US) of patients treated with sorafenib. 
AEs were the most commonly reported reason for reduced 
dosage for sunitinib [29.2% (US), 37.1% (Europe), and 36.8% 
(Asia)], and sorafenib [43.5% (US), 20.4% (Europe), and 
31.3% (Asia)]. After the discontinuation of first-line treat-
ment, 20.4% (US) to 24.0% (Asia) of patients treated with 
sunitinib, 31.3% (Asia) to 50.0% (Europe) of patients treated 
with sorafenib, and 59.1% (US) to 70.0% (Europe) of patients 
treated with bevacizumab received second-line therapy.
Table IV describes specific AEs reported as reasons for 
first-line treatment modifications. Among the AEs of interest, 
vomiting was the most common AE leading to discontinua-
tion of first-line sunitinib in the US (21.6%), fatigue/asthenia 
was most common in Europe (32.7%), and mucositis or 
stomatitis was the most common reason in Asia (34.8%). 
For sorafenib, skin rash most commonly led to treatment 
discontinuation in the US (27.8%); diarrhea and hand-foot 
syndrome most commonly led to discontinuation in Europe 
(37.5%). The most common AEs reported as reason for dose 
reduction for sunitinib varied across regions: diarrhea in US 
(25.5%), fatigue in Europe (31.5%) and mucositis or stoma-
titis in Asia (26.1%). Skin rash was the most common AE 
for dose reduction among sorafenib patients in US (31.6%), 
and hand-foot syndrome was the most common reason in 
Europe (44.4%).
Discussion
Findings from the current study with data from 883 patients 
contribute to the growing body of knowledge on the use of 
sunitinib, sorafenib and bevacizumab as first-line agents 
among patients with advanced RCC treated in real-world 
clinical practice across different geographical regions. 
Tolerability and management of side-effects for patients 
receiving sunitinib, sorafenib and bevacizumab as first-line 
anti-angiogenesis treatment for advanced RCC are significant 
issues for patients and the physicians who care for them.
There were variations in treatment and outcomes across 
global regions. In the US and Europe, patients receiving suni-
tinib were almost twice as likely as those in Asia to initiate 
therapy at 50 mg QD 4/2. This observation raises the issue 
relative to the use of fixed doses of suntinib (and also of all 
molecularly targeted agents), irrespective of parameters like 
gender and body weight/body surface area. Indeed, a popu-
lation pharmacokinetic analysis identified low body weight 
(and female gender) as covariates that significantly increase 
exposure to sunitinib, potentially leading to increased 
toxicity (23). Moreover, the most commonly experienced AEs 
also varied across region. In the US and Europe, fatigue was 
the most common AE among patients receiving sunitinib, 
sorafenib and bevacizumab while hand-foot syndrome was 
the most common AE in Asian patients receiving sunitinib or 
sorafenib. Notably, the AEs most commonly leading to treat-
ment discontinuation also varied.
Despite these differences, there were some universal find-
ings across settings. Notably, the median treatment duration 
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with that reported in RCTs and EAPs. The median treatment 
duration for sunitinib was 11 and 16.6 months in the RCT 
and EAP (4,7), respectively, whereas the median ranged from 
6.1 to 10.7 months across regions in this study. Similarly, the 
median treatment duration for sorafenib was 12 months in 
the EAP (8) whereas it ranged from 5.1 to 8.5 months across 
regions in the current analysis. For bevacizumab the median 
treatment duration was 9.7 months in one RCT (24) and 
8.2 months in another RCT (25) whereas it ranged from 7.5 to 
9.8 months across regions in this study.
Treatment discontinuation was high, reaching 63.1% 
among sunitinib patients in the US, 90.0% among sorafenib 
patients in Europe, and 81.8% of bevacizumab patients in US. 
For patients who discontinued sunitinib treatment due to AEs 
the average number of AEs per discontinuation was 2.3-2.5 
across regions; for sorafenib it was 1.9-3.1. This illustrates 
that in real-world practice physicians manage multiple AEs 
per patient and may discontinue or modify treatment based on 
the observed effects of these AEs. The proportion of patients 
with any type of treatment modification due to an AE was also 
consistently high across all regions, reaching 59.2% among 
sunitinib patients in Asia, 64.1% among sorafenib patients in 
US and 53.3% of bevacizumab patients in Europe.
This study builds upon prior evidence from RCTs and 
EAPs on the toxicity and treatment patterns of angiogenesis 
inhibitors. Similar to results in this global chart review study, 
treatment discontinuation was high in RCTs and EAPs. 
In the RCT comparing sunitinib to interferon α, 86% of 
patients experienced a treatment discontinuation (versus 62.4 
to 63.1% in the current study) (4). In the EAP for sorafenib, 
100% of patients experienced a treatment discontinuation 
(versus 68.8 to 90.0% in the current study) (8). In the RCT 
comparing bevacizumab plus interferon to placebo, 72% of 
patients experienced a treatment discontinuation (versus 
66.7 to 81.8% in the current study) (24). In RCTs, diarrhea 
was the most commonly reported AE for both sunitinib and 
sorafenib (versus fatigue in the US and Europe, and hand-foot 
syndrome in Asia in the current study) and anorexia was the 
most commonly reported AE for bevacizumab (versus fatigue 
in the current study for US and Europe) (4,8,24). In EAPs 
for sunitinib and sorafenib, the most commonly reported AEs 
were diarrhea and hand-foot syndrome.
Differences with RCT may arise due to differences in 
the underlying study populations as well as how data are 
collected. For example, the proportion of patients with brain 
metastasis in the current study were 7.0, 7.2 and 11.1%, for 
sunitinib, sorafenib and bevacizumab, respectively, while 
these patients were excluded in RCTs. Besides, RCTs have 
well-defined operational definitions for AE identification 
and gradation, as well as a rigorous protocol to capture them 
whereas in a retrospective setting such as in the current study, 
AEs are captured based on the treating physicians' reports 
and judgments. Sometimes physicians may record only those 
AEs that lead to a treatment modification or if the AEs are 
severe enough to warrant specific treatment; therefore, under-
reporting of AEs in this study may have occurred.
Findings from this study were generally consistent with 
those from other observational studies (14-20). In the Korean 
study by Hong et al (14), 76% of sunitinib patients had a dose 
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discontinued due to toxicity. A high proportion of patients in 
that study (>75%) experienced fatigue, anorexia and hand-foot 
syndrome. In the Korean study by Hwang et al (15), 29% of 
sunitinib patients experienced a dose reduction. In the UK 
study by Ansari et al (16), 15% of sunitinib patients experi-
enced a dose discontinuation in their first cycle of treatment, 
and 75% experienced at least one dose reduction. Notably, the 
number of patients in the current study was several fold higher 
than the aforementioned observational studies.
Some disparities in study results between this study and 
other observational studies reported above may have occurred 
due to differences in treatment durations, frequency of patient 
visits where AEs are reported, incomplete or inadequate 
recording of AEs, and differences in practice patterns rela-
tive to management of AEs across countries. Differences in 
drug approval dates, affecting drug availability, could have 
affected practice patterns as well. Differences in healthcare 
should also be kept in mind while making comparisons across 
studies.
There are some limitations associated with this study. 
Since data collection for this study preceded marketing 
authorization for pazopanib in Europe, this study does not 
include information on patients receiving pazopanib as 
first-line treatment. Further, due to the small sample sizes in 
certain groups for some regions, especially bevacizumab in 
all regions and sorafenib in Asia, the findings reported are 
descriptive in nature.
This multi-country study provides evidence that AEs 
are common in patients with advanced RCC treated with 
angiogenesis inhibitors, and that these AEs often lead to 
treatment modifications in the real-world clinical setting. 
This real-world practice study suggests that management of 
toxicities associated with anti-angiogenic agents for the treat-
ment of advanced RCC presents significant issues for treating 
physicians and patients. The findings from this study further 
underscore the continued need for novel tolerable treatment 
options for advanced RCC. Additionally, the results of this 
study show the potential benefits of use of observational 
studies to further understand real-world treatment patterns 
and outcomes, beyond information that may be available from 
other data sources.
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